IMCR — Immunocore Holdings plc American Depositary Shares price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
Key stats#
Data provided bySource: Twelve DataPrice data
- Price
- $29.94
- YTD price return
- -13.74%
- YTD total return
- -13.74%
- Market cap
- 1.5B
- Enterprise value
- 1.1B
- Shares outstanding
- 51.7M
- 52W low
- $27.50
- 52W high
- $40.72
- From 52W high
- -26.46%
- From 52W low
- +8.87%
- 52W range
- 18%$27.50–$40.72
Volume
- Rel volume
- 0.51×
- 30D volume
- 525.6K
- 30D $ vol
- 16M
Fundamentals
- Sales (ttm)
- 429.3M
- Sales/share
- $8.31
- EPS (ttm)
- -$0.62
- FCF (ttm)
- -18.2M
- FCF/share
- -$0.35
- Book value/share
- $8.12
- Net margin
- -7.48%
- ROE
- -7.65%
- ROA
- -2.84%
- Debt / equity
- 0.94×
- Current ratio
- 4.62
Growth (CAGR, ttm) · 10Y
- Sales
- +13.11%+21.84%+68.08%n/a
- Shares
- +2.28%-1.55%+3.52%n/a
Per-share growth (CAGR, ttm) · 10Y
- Sales/share
- +10.59%+20.23%+62.37%n/a
- Book value/share
- +3.48%+7.30%+9.50%n/a
- Price
- -15.36%-15.73%-5.43%n/a
- Total return
- -15.36%-15.73%-5.43%n/a
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- -48.0×
- Fwd P/E
- -49.6×
- P/S (ttm)
- 3.6×
- P/B (mrq)
- 3.7×
- EV/Sales (ttm)
- 2.5×
- FCF yield (ttm)
- -1.18%
- Buyback yield (realized, 1y)
- -2.28%
- Shareholder yield (realized, 1y)
- -2.28%
- Buyback yield (cash, ttm)
- 0.00%
- Shareholder yield (cash, ttm)
- 0.00%
Vs own 10Y history
- P/S
- 4th
- P/B
- 3rd
Bar = where today’s multiple sits in IMCR’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).
Performance · price returntotal return · as of 2026-11-13#
Data provided bySource: Twelve DataFundamentals#
Operating income
5Y n/m5Y n/mYoY n/mEPS (diluted)
5Y n/m5Y n/mYoY n/mFree cash flow
5Y n/m5Y n/mYoY n/mTTM: operating cash flow −$10.4M, capex −$7.8M
Q3 2026: operating cash flow $20.1M, capex −$2.3M
Shares (diluted)
5Y +89.8%5Y +89.8%YoY +2.3%Dividend per share
5Y n/m5Y n/mNo quarters filed for this figure.
About Immunocore Holdings ADR#
Data provided bySource: Twelve DataImmunocore Holdings plc ADR is a commercial-stage biotechnology company focused on developing T cell receptor-based immunotherapies designed to help the immune system recognize and eliminate diseased cells. Immunocore’s lead marketed product, KIMMTRAK, is used to treat unresectable or metastatic uveal melanoma, while its broader platform supports research and development across oncology, infectious diseases, and autoimmune disorders. The company’s ImmTAX technology underpins a portfolio of current and investigational therapies aimed at harnessing or redirecting immune responses with precision. Immunocore serves patients and healthcare providers through specialized therapies that address serious, hard-to-treat conditions, and its programs span clinical development as well as commercial operations in key international markets. Headquartered in Abingdon, United Kingdom, Immunocore Holdings plc ADR remains a notable participant in the biotechnology sector through its focus on novel immune-based medicines.
Abingdon, United Kingdom·497 employees·Biotechnology·immunocore.com·As of Oct 28, 2026
ETFs holding IMCR#
2 of the 193 ETFs ChartRow carries live hold IMCR. Their positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).
| Fund | Name | Filed weight |
|---|---|---|
| IBB | iShares Biotechnology ETF | 0.1% |
| ONEQ | Fidelity Nasdaq Composite Index ETF | 0.0% |
Related Healthcare#
Data provided bySource: Twelve Data| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | +23.75% | +1.14% |
| JNJ | Johnson & Johnson | +14.94% | +0.79% |
| ABBV | AbbVie Inc. | +7.53% | +0.20% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | +7.86% | +0.58% |
| MRK | Merck & Co. Inc. | +4.07% | +0.55% |
| NVS | Novartis AG | +12.70% | +0.16% |
| TMO | Thermo Fisher Scientific Inc. | +5.61% | +0.11% |
| AMGN | Amgen Inc. | +12.80% | -0.30% |
